Loteprednol etabonate: A soft steroid for the treatment of allergic diseases of the airways

Drugs of Today

Volumn 36, Issue 5, 2000, Pages 313-320

  Szelenyi, Istvan ^b   Hochhaus, Günther ^a,b   Heer, Sabine ^b   Küsters, Sabine ^b   Marx, Degenhard ^b   Poppe, Hildegard ^b   Engel, Jürgen ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b ASTA MEDICA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; CYTOCHROME P450; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE; GLUCOCORTICOID RECEPTOR; LOTEPREDNOL ETABONATE; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG POTENCY; DRUG RECEPTOR BINDING; EOSINOPHILIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG LAVAGE; NONHUMAN; PLASMA PROTEIN BINDING; RESPIRATORY TRACT ALLERGY; REVIEW; RHINORRHEA; STEROID THERAPY; THYMUS;

EID: 0034079575     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.5.575043     Document Type: Review

References (58)

1. Howarth, P.H., Holmberg, K. Allergic rhinitis: An increasing clinical problem. Allergy 1995, 50: 4-5.
2. Lund, V.J. Seasonal allergic rhinitis - A review of current therapy. Allergy 1996, 51: 5-7.
3. Malone, D.C., Lawson, K.A., Smith, D.H., Arrighi, H. M., Battista, C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997, 99: 22-7.
4. Weeke, E.R. Epidemiology of allergic diseases in children. Rhinology 1992, 13 (Suppl.): 5-12.
5. Bachert, C. Von der allergischen Rhinitis zum Pollenasthma und retour. Forschung Praxis 1997, 234: 3-4.
6. Djukanovic, R., Wilson, S.J., Howarth, P.H. Pathology of rhinitis and bronchial asthma. Clin Exp Allergy 1996, 26 (Suppl.): 44-51.
7. Vignola, A.M., Chanez, P., Godard, P., Bousquet, J. Relationships between rhinitis and asthma. Allergy 1998, 53: 833-9.
8. Siegel, S.C. Topical intranasal corticosteroid therapy in rhinitis. J Allergy Clin Immunol 1988, 81: 984-91.
9. LaForce, C.F., Dockhorn, R.J., Findlay, S.R. Fluticasone proprionate: An effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Phys 1994, 38: 145-52.
10. Wenzel, S.E. Should antileukotriene therapies be used instead of inhaled corticosteroids in asthma? Am J Respir Crit Care Med 1998, 158: 1699-701.
11. Cumming, R.G., Mitchell, P., Leeder, S.R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997, 337: 8-14.
12. Quintiliani, R. Hypersensitivity and adverse reactions associated with the use of newer intranasal corticosteroids for allergic rhinitis. Curr Ther Res 1996, 57: 478-88.
13. Saha, M.T., Laippala, P., Lenko, H.L. Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids. Acta Paediatr 1997, 86: 138-42.
14. Todd, G., Dunlop, K., McNaboe, Ryan, M.F., Carson, D., Shields, M.D. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone proprionate. Lancet 1996, 348: 27-9.
15. Barnes, N.D., Whitaker, K., Gelson, W., Barnes, J.L.C. The effect of inhaled dry powder corticosteroids on growth in children with asthma. Horm Res 1997, 48 (Suppl. 2): 76.
16. Wolthers, O.D., Pedersen, S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993, 82: 635-40.
17. Efthimiou, J., Barnes, P.J. Effect of inhaled corticosteroids on bones and growth. Eur Respir J 1998, 11: 1167-77.
18. Bodor, N. The application of soft drug approaches to design safer steroids. In: Topical Corticosteroid Therapy: A Novel Approach to Safer Drugs. E. Christophers (Ed.). Raven: New York 1988, 13-25.
19. Beato, M., Rousseau, G.G., Feigelson, P. Correlation between glucocorticoid binding to specific liver cytosol receptors and enzyme induction. Biochem Biophys Res Commun 1972, 47: 1464-72.
20. Dahlberg, E., Thalen, A., Brattsand, R. et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16α,17α-acetal-substituted-glucocorticoids. Mol Pharmacol 1984, 25: 70-8.
21. Druzgala, P., Hochhaus, G., Bodor, N. Soft drugs. 10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: Loteprednol etabonate. J Steroid Biochem Mol Biol 1991, 38: 149-54.
22. Hochhaus, G., Druzgala, P., Hochhaus, R., Huang, M.-J., Bodor, N. Glucocorticoid activity and structure activity relationships in a series of some novel 17α-ether-substituted steroids: Influence of 17α-substituents. Drug Des Deliv 1991, 8: 117-25.
23. Hochhaus, G. Binding affinities of commercially available glucocorticoids to the glucocorticoid receptor of the human lung. Institute of Pharmaceutical Chemistry, Westfaelische Wilhelms Universitaet, Muenster 1983.
24. Hochhaus, G., Möllrnann, H. Binding affinities of rimexolone (Org 6216), flunisolide and their putative metabolites for the glucocorticoid receptor of human synovial tissue. Agents Actions 1990, 30: 377-80.
25. Hogger, P., Rohdewald, P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994, 59: 597-602.
26. Smith, C.L., Kreutner, W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneim-Forsch/Drug Res 1998, 48: 956-60.
27. Barnes, P.J. Mechanisms of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996, 154: S21-7.
28. Gasson, J.C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 1991, 77: 1131-45.
29. Lemoli, R.M., Fogli, M., Fortuna, A. et al. Interleukin 11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR-cells and synergises with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor. Exp Hematol 1993, 21: 1668-72.
30. Monroy, R.L., Davis, T.A., MacVittie, T.J. Granulocyte-macrophage colony-stimulating factor: More than a hemopoietin. Clin Immunol Ommunopathol 1990, 54: 333-46.
31. Warringa, R.A., Koenderman, L., Kok, P.T., Kreukniet, J., Bruijnzeel, P.L. Modulation and induction of eosinophil chemotaxis by granulocyte-macrophage colony-stimulating factor and interleukin-3. Blood 1991, 77: 2694-700.
32. Djukanovic, R. Nasal polyps - A model of chronic respiratory mucosal inflammation. Clin Exp Allergy 1995, 25: 582-5.
33. Kawabori, S., Denburg, J.A., Schwartz, L.B. Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. Am J Respir Cell Mol Biol 1992, 6: 37-43.
34. Otsuka, H., Ohkubo, K., Seki, H., Ohnishi, M., Fujikura, T. Mast cell quantitation in nasal polyps, sinus mucosa and nasal turbinate mucosa. J Laryngol Otol 1993, 107: 418-22.
35. Stoop, A.E., vander Heijden, H.A., Biewenga, J., vander Baan, S. Eosinophils in nasal polyps and nasal mucosa: An immunohistochemical study. J Allergy Clin Immunol 1993, 91: 616-22.
36. Linder, A., Karlsson-Parra, A., Hirvela, C., Jonsson, L., Koling, A., Sjoberg, O. Immunocompetent cells in human nasal polyps and normal mucosa. Rhinology 1993, 31: 125-9.
37. Shulman, D.G., Lothringer, L.L., Rubin, J.M. et al. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis. Ophthalmology 1999, 106: 362-9.
38. Barlett, J.D., Horwitz, B., Laibovitz, R., Howes, J.F. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993, 9: 157-65.
39. Novack, G.D., Howes, J., Crockett, R.S., Sherwood, M.B. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma 1998, 7: 266-9.
40. Stroman, F., Erdmann, R., Szelenyi, I. Nasal perfusion in anaesthetized rats, a model of various types of rhinitis. Arch Pharmacol 1993, 347 (Suppl.): R110.
41. Takahashi, N., Aramaki, Y., Tsuchiya, S. Allergic rhinitis model with Brown Norway rat and evaluation of antiallergic drugs. J PharmacobioDyn 1990, 13: 414-20.
42. Poppe, H., Marx, D., Szelenyi, I. Comparison of the therapeutic effects of loteprednol, beclomethasone and fluticasone in preclinical models of allergic rhinitis and airway inflammation and on thymus weight in rats. Eur Respir J 1999, 14 (Suppl. 30): 158s.
43. Poppe H., Küsters, S., Szelenyi, I. Effect of AWD 12-281, a new selective PDE4-inhibitor, loteprednol and beclomethasone in models of allergic rhinitis and airway inflammation in Brown Norway rats. Am J Respir Crit Care Med 1999, 159 (Suppl. 3): A95.
44. Mudde, G.C., Bheekha, R., Bruijnzeel-Koomen, C.A.F.M. IgE-mediated antigen presentation. Allergy 1995, 50: 193-9.
45. Djukanovic, R., Roche, W.R., Wilson, J.W. et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990, 142: 434-57.
46. Howarth, P.H. The cellular basis for allergic rhinitis. Allergy 1995, 50: 6-10.
47. Poppe H., Marx, D., Heer, S., Szelenyi, I. Effects of loteprednol etabonate on TNFα and GM-CSF release in vitro and on late phase allergic eosinophilia in guinea pigs administered intratracheally as a dry powder. Am J Respir Crit Care Med 1998, 157 (Suppl. 3): A522.
48. Poppe, H., Szelenyi, I. Effect of topically administered loteprednol etabonate on allergic rhinitis in Brown-Norway rats and on late phase allergic eosinophilia in guinea pigs. Arch Pharmacol 1998, 358 (Suppl. 1): R327.
49. Bodor, N., Loftsson, T., Wu, W.M. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res 1992, 9: 1275-8.
50. Hochhaus, G., Chen, L.-S., Ratka, A. et al. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs. J Pharm Sci 1992, 81: 1210-5.
51. Bodor, N., Wu, W.M., Murakami, T., Engel, S. Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 1995, 12: 875-9.
52. Hochhaus, G., Moellmann, H., Derendorf, H., Gonzalez-Rothi, R. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997, 37: 881-92.
53. Chanoine, F., Grenot, C., Heidmann, P., Junien, J.L. Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate In the rat after intratracheal, intravenous, and oral treatments. Drug Metab Dispos 1991, 19: 546-53.
54. Ryrfeldt, A., Toennesson, M., Nilsson, E., Wikby, A. Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography. J Steroid Biochem 1979, 10: 317-24.
55. Howes, J., Novack, G.D. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, PJ-91, following chronic ocular administration. J Ocul Pharmacol Ther 1998, 14: 153-8.
56. Andersson, P., Brattsand, R., Dahlstroem, K., Edsbaecker, S. Oral availability of fluticasone propionate. Br J Clin Pharmacol 1993, 36: 135-6.
57. Brogden, R.N., McTavish, D. Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992, 44: 375-407.
58. Derendorf, H., Hochhaus, G., Rohatagi, S. et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995, 35: 302-5.